A5089953149- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Asthma and respiratory diseases
- Health Systems, Economic Evaluations, Quality of Life
- Allergic Rhinitis and Sensitization
- Nonmelanoma Skin Cancer Studies
- Colorectal and Anal Carcinomas
- Genital Health and Disease
- Cervical Cancer and HPV Research
- Hidradenitis Suppurativa and Treatments
- Autoimmune Bullous Skin Diseases
- Pharmaceutical studies and practices
- Skin and Cellular Biology Research
- Infectious Diseases and Mycology
- Chemotherapy-related skin toxicity
- Anorectal Disease Treatments and Outcomes
- Rheumatoid Arthritis Research and Therapies
- Urticaria and Related Conditions
- Autoimmune and Inflammatory Disorders Research
- Nail Diseases and Treatments
- Food Allergy and Anaphylaxis Research
- Immunodeficiency and Autoimmune Disorders
- Cutaneous lymphoproliferative disorders research
- Acne and Rosacea Treatments and Effects
- Skin Diseases and Diabetes
Université de Sherbrooke
1994-2022
Moncton Hospital
2009-2021
Centre Méditerranéen de Médecine Moléculaire
2019
Memorial University of Newfoundland
2015-2017
University of Toronto
2015-2017
University of British Columbia
2013-2017
Dermatrials Research
2015-2017
Western University
2017
University of Alberta
2017
University of Calgary
2017
Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well determine eligibility criteria clinical studies. However, owing the heterogeneity of classifications and their lack consideration impact psoriasis involvement special areas or past history, patients may be miscategorized, which can lead undertreatment psoriasis.To develop a consensus statement on classification severity.A modified Delphi approach was developed by International Council...
The response of psoriasis to antibodies targeting the interleukin (IL)-23/IL-17A pathway suggests a prominent role T-helper type-17 (Th17) cells in this disease. We examined clinical and immunological patterns 100 subjects with moderate-to-severe receiving 3 different intravenous dosing regimens anti-IL-17A antibody secukinumab (1 × mg/kg or 1 10 on Day 1, Days 15 29) placebo phase 2 trial. Baseline biopsies revealed typical features active psoriasis, including epidermal accumulation...
Most patients with psoriasis have nail changes, and treating is challenging.To assess improvement in fingernail ustekinumab treatment the PHOENIX 1 trial.Patients received 45 mg or 90 mg, placebo at weeks 0 4. Ustekinumab-randomized continued maintenance dosing every 12 weeks, while receiving crossed over to receive 12/16 followed by weeks. At week 40, initial responders [those ≥ 75% from baseline Psoriasis Area Severity Index (PASI 75)] were rerandomized either continue withdraw treatment....
Engaging global key opinion leaders, the International Psoriasis Council (IPC) held a day-long roundtable discussion with primary purpose to discuss treatment goals of psoriasis patients and worldwide barriers optimal care. Setting clear expectations might ultimately encourage undertreated seek care in an era which great gains therapeutic efficacy have been achieved. Here, we option for early all categories alleviate disease impact while emphasizing need more focused attention mild moderate...
Abstract Background Biological agents targeting IL ‐17 are very effective for clearing moderate to severe psoriasis. There is limited information regarding the frequency and pattern of psoriasis relapse upon treatment cessation. Objective To investigate recurrence in patients who were treated with brodalumab following Amgen's decision stop clinical programme June 2015. Materials methods Between 2015 March 2016, we constructed a retrospective multicenter cohort study including protocols after...
<i>Background:</i> Effective and safe products are needed for long-term management of scalp psoriasis. This study investigated the safety efficacy a two-compound formulation (calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g) <i>Methods:</i> In this 52-week, international, double-blind study, 869 patients with moderate-to-severe psoriasis were randomized to either (n = 429) or calcipotriol 440). <i>Results:</i> Adverse drug reactions less...
Abstract Background Ustekinumab, a human anti‐interleukin‐12/23 monoclonal antibody, has been shown to effectively treat moderate‐to‐severe psoriasis which significantly affects health‐related quality of life (HRQoL), including patients’ sexual lives. Objectives The aim this study was determine if difficulties associated with are related disease severity and whether improve skin during ustekinumab treatment. Methods In phase III PHOENIX 1 2 trials, patients were randomized ( n = 1334) at...
Objective: To assess the effect of ustekinumab on productivity and work limitations among 1230 psoriasis patients treated with 45 mg or 90 placebo during Phase III PHOENIX 2 trial. Methods: The self-administered Work Limitations Questionnaire (WLQ) was used to determine on-the-job at baseline weeks 12 24. Productivity assessed using a Visual Analog Scale (VAS), number days missed due recorded. Results: At baseline, were similar across treatment groups. week 12, improvement in VAS scores...
Objective: Explore the feasibility of Treat to Target in area psoriasis as seen other therapeutic areas such hypertension, hyperlipidemia, diabetes and rheumatoid arthritis. Methods: Review validated, measurable targets for psoriasis, including physician global assessment (PGA), severity index (PASI) dermatology life quality (DLQI). Examine principles brought forth published European consensus on develop a Canadian psoriasis. Results: As PASI DLQI are not routinely used community setting, we...
Squamous cell carcinoma (SCC) is the second-most common form of non-melanoma skin cancer (NMSC).To provide guidance to Canadian health care practitioners regarding management SCCs.Literature searches and development graded recommendations were carried out as discussed in accompanying introduction (chapter 1 NMSC guidelines).SCCs are sometimes confined epidermis, but they can also invade nearby tissues and, some cases, metastasize neighbouring lymph nodes or other organs. This chapter...